THERAVET SA 
The specialist of osteoarticular disease treatments in companion animals
DISCLAIMER
This document may not be forwarded or distributed, in whole or in part, under any circumstances. Failure to comply with these restrictions may constitute a violation of applicable securities laws. By accepting this document, you acknowledge and agree to the following: This document and the information contained in the presentation are strictly confidential. This document may not be copied, reproduced, distributed, released or disclosed, directly or indirectly, in whole or in part, to any other person (whether internally or externally to your company). In particular, neither this document, nor any part or copy of it may be distributed directly or indirectly in the United States, Canada, Australia or Japan. Non- compliance with these restrictions may result in the violation of legal restrictions in certain jurisdictions. This presentation does not constitute or form part of, and should not be construed as, an offer of securities for sale or an invitation or inducement to invest in securities of THERAVET (the "Company") in France, in Belgium, the United States or any other jurisdiction and neither it nor any part of it shall form the basis of, or be relied upon in connection with, any contract, commitment or investment decision in relation thereto. Securities may not be offered or sold in the United States absent registration or an exemption from registration.. No public offering of securities may be conducted in France or in Belgium prior to the delivery by Euronext Paris of an approval on an offering Circular (the "Offering Circular"). Any decision to purchase securities of the Company should be made solely on the basis of information contained in the Offering Circular, which may contain material information that is not contained herein and which shall supersede this information in its entirety. No public offering of securities is contemplated in any jurisdiction outside France or Belgium. In particular, no securities will be registered under the US Securities Act of 1933, as amended (the "Securities Act"), or with any securities regulatory authority of any state or other jurisdiction in the United States. Securities may not be offered or sold in the United States absent registration or pursuant to an exemption from the registration requirements of the U.S. Securities Act of 1933, as amended. The shares of the Company have not been and will not be registered under the U.S. Securities Act of 1933, as amended. If any securities are offered and sold in the United States, they would be subject to restrictions. In the United States this document is being distributed to and is only directed to qualified institutional buyers, as defined in Rule 144A of the Securities Act and otherwise in compliance with applicable securities regulations. Each recipient of this presentation in the United States is deemed to represent and warrant that it is a qualified institutional buyer. This presentation includes only summary information and does not purport to be comprehensive. Any information in this document, whether from internal or from external sources, is purely indicative and has no contractual value. The information contained in this presentation are provided as at the date of this presentation. Certain information included in this presentation and other statements or materials published or to be published by the Company are not historical facts but are forward-looking statements. The forward-looking statements are based on current beliefs, expectations and assumptions, including, without limitation, assumptions regarding present and future business strategies and the distribution environment in which the Company operates, and involve known and unknown risk, uncertainties and other factors, which may cause actual results, performance or achievements, or industry results or other events, to be materially different from those expressed or implied by these forward-looking statements. The Company may not actually achieve the plans, intents or expectations disclosed in its forward-looking statements and you should not place undue reliance on the forward-looking statements contained herein. There can be no assurance that the actual results of the Company's development activities and results of operations will not differ materially from the Company's expectations. Factors that could cause actual results to differ from expectations include, among others, the Company's ability to develop safe and effective products; to achieve positive results in clinical trials; to obtain marketing approval and market acceptance for its products; to manufacture its products; and to enter into and maintain collaboration, licensing and supply agreements; as well as the impact of competition and technological change; existing and future regulations affecting the Company's business; and the future scope of the Company's patent coverage or that of third parties. No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information, or opinions contained herein. Neither the Company, nor any of their respective affiliates, advisors or representatives, shall bear any responsibility or liability whatsoever (for negligence or otherwise) for any loss howsoever arising from any use of this presentation or its contents or otherwise arising in connection with this presentation. Such information is subject to modification at any time, including without limitation as a result of regulatory changes or changes with respect to market conditions, and the Company has any duty to, update you. If an offer of securities is made by the Company in the future, prospective investors should rely solely on (i) the Offering Circular or offering memorandum to be prepared by the Company for the purposes of such offering, including in particular the risk factors described therein, (ii) any notices that are published by the Company and that expressly amend the terms of the offering, and (iii) any examinations of the Company that any prospective investor may deem necessary. No reliance may be placed for any purposes whatsoever on the information contained in this presentation, or on its completeness, accuracy or fairness. It is the responsibility of each prospective investor, if an offer of securities is made in the future, to review the Offering Circular carefully and to make an independent assessment of the risks and merits of the offering. The securities may be subject to other restrictions on transferability and resale under applicable securities legislation, and it will be the responsibility of prospective investors to inform themselves about such restrictions. The Company do not and will not assume any legal responsibility for any violation of applicable restrictions.
An experienced, complementary and committed team
Julie SCHURGERS | Enrico BASTIANELLI | Julie WINAND | ||||||||
Commercial Director | Founder & CEO | Chief Corporate Officer, | ||||||||
MD, MBA | PhD | |||||||||
16 years of experience in | 25 years of experience in the | 8 years of experience in the | ||||||||
veterinary product marketing | pharma & biotech sector | pharma & biotech sector | ||||||||
and sales | ||||||||||
Expertise: | Expertise: | Expertise: | ||||||||
bone, joints and orthopedics | business and product development | |||||||||
pet health business & marketing | ||||||||||
Founder & CEO of Bone | Bone Therapeutics, Novasep | |||||||||
MSD Animal Health | ||||||||||
Therapeutics, ProSkelia, | ||||||||||
Belgium, Elanco | ProStrakan, McKinsey & Co | |||||||||
Sabrina ENA
Chief Operating Officer,
PhD
8 years of experience in the pharma & biotech sector
Expertise:
preclinical, clinical and regulatory
Bone Therapeutics
March 2022 | 3 |
The crucial pet health sector issues
Strong bonds between pets | Vets seeking for adequate treatments |
and their owners | |
The health of pets, | Few innovative treatments, |
being family members, is at the heart | essentially symptomatic, |
of their owner concerns | and a need for curative treatments |
March 2022 | 4 |
A market with strong structural trends…
A major market that is growing fast
and is resilient to crises
Positive and complementary
market drivers
The pet market represents | Dominated (>75%) |
>40% of the global animal | by the United States |
healthcare market (2018)(1) | and Europe(2)(3) |
Pet market in $ billion(4)(5)
+5.7% CAGR
6.0% CAGR
24 | |||||||||
16 | |||||||||
9 | |||||||||
2010 | 2018 | 2026 | |||||||
(1) Animal Health Update July 24, 2018, Credit Suisse | |||||||||
(2) Horspool, L. J. I. (2012). Animal Health Markets and Opportunities: Companion Animal Landscape | |||||||||
March 2022 | 5 | (3) https://www.datamintelligence.com/research-report/companion-animal-health-market | |||||||
(4)https://www.acumenresearchandconsulting.com/companion-animal-health- market |
(5) https://www.statista.com/statistics/260185/global-animal-health-market/
Pets
Growth in the number of pets
Increase in life expectancy Growth of comorbidities
Pet owners
Increase in the number of pet- owning households
In need of new treatments
Increase of health
Vets
Increase of the number of vets
Structuration in clinics and networks Increase of the offer of sophisticated treatments
Pour lire la suite de ce noodl, vous pouvez consulter la version originale ici.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Theravet SA published this content on 08 March 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 March 2022 15:51:04 UTC.
